Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Zai Lab	Ascendis Pharma A/S	Arrowhead Pharmaceuticals	ACADIA Pharmaceuticals	Jazz Pharmaceuticals
Symbol	NASDAQ:ZLAB	NASDAQ:ASND	NASDAQ:ARWR	NASDAQ:ACAD	NASDAQ:JAZZ
Price Information
Current Price	$164.48	$131.85	$70.99	$20.87	$167.52
52 Week Range	Buy	Buy	Buy	Hold	Buy
MarketRank™
Overall Score	1.4	1.5	1.3	1.9	2.1
Analysis Score	2.5	3.5	2.4	4.2	3.4
Community Score	2.3	2.6	2.5	3.2	3.4
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	1.7	0.8	1.7	1.7	1.7
Earnings & Valuation Score	0.6	0.6	0.0	0.6	1.9
Analyst Ratings
Consensus Recommendation	Buy	Buy	Buy	Hold	Buy
Consensus Price Target	$197.85	$192.22	$85.31	$32.76	$187.37
% Upside from Price Target	20.29% upside	45.79% upside	20.17% upside	56.99% upside	11.85% upside
Trade Information
Market Cap	$14.57 billion	$7.09 billion	$7.37 billion	$3.34 billion	$9.44 billion
Beta	0.95	0.77	1.62	1.44	1.08
Average Volume	471,913	208,665	795,625	2,192,327	710,664
Sales & Book Value
Annual Revenue	$12.98 million	$14.98 million	$87.99 million	$339.08 million	$2.16 billion
Price / Sales	1,122.62	473.09	83.74	9.85	4.36
Cashflow	N/A	N/A	N/A	N/A	$22.82 per share
Price / Cash	N/A	N/A	N/A	N/A	7.34
Book Value	$5.07 per share	$15.87 per share	$4.51 per share	$4.54 per share	$54.99 per share
Price / Book	32.44	8.31	15.74	4.60	3.05
Profitability
Net Income	$-195,070,000.00	$-244,180,000.00	$-84,550,000.00	$-235,260,000.00	$523.37 million
EPS	($3.03)	($5.25)	($0.84)	($1.60)	$14.60
Trailing P/E Ratio	N/A	N/A	N/A	N/A	52.85
Forward P/E Ratio	N/A	N/A	N/A	N/A	10.96
P/E Growth	N/A	N/A	N/A	N/A	4.64
Net Margins	N/A	-4,042.79%	-96.09%	-63.92%	7.86%
Return on Equity (ROE)	N/A	-55.72%	-17.37%	-40.35%	20.16%
Return on Assets (ROA)	N/A	-49.42%	-15.19%	-34.72%	10.85%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	N/A	N/A	N/A	N/A	0.55%
Current Ratio	8.57%	14.80%	7.92%	7.95%	3.98%
Quick Ratio	8.46%	14.80%	7.92%	7.86%	3.84%
Ownership Information
Institutional Ownership Percentage	81.32%	N/A	65.52%	93.54%	95.67%
Insider Ownership Percentage	N/A	40.00%	4.00%	27.70%	4.60%
Miscellaneous
Employees	1,194	482	232	601	1,940
Shares Outstanding	88.59 million	53.75 million	103.79 million	160.05 million	56.33 million
Next Earnings Date	N/A	5/18/2021 (Estimated)	5/4/2021 (Confirmed)	5/5/2021 (Confirmed)	5/4/2021 (Confirmed)
Optionable	Optionable	Optionable	Optionable	Optionable	Optionable

Source	Headline
	BRIEF-Jazz Pharmaceuticals Prices $1.5 Billion Senior Secured Notes Offering msn.com - April 22 at 7:36 PM
	Jazz Pharmaceuticals Prices $1.5 Billion Senior Secured Notes Offering finance.yahoo.com - April 22 at 7:36 PM
	Sulglicotide API Market Size 2021-Top Companies, Growth Rate, Trends, Product Profiles, Development Plans and Demand Status Forecast to 2025 marketwatch.com - April 22 at 9:36 AM
	Jazz Pharmaceuticals (NASDAQ:JAZZ) PT Raised to $198.00 at Cantor Fitzgerald americanbankingnews.com - April 21 at 9:42 AM
	Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target Raised to $198.00 at Cantor Fitzgerald marketbeat.com - April 21 at 7:48 AM
	Novel Approach to Cancer From Lixte Biotechnology Could Be a General way to Enhance a Variety of Standard Treatments markets.businessinsider.com - April 20 at 2:19 PM
	Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target Increased to $202.00 by Analysts at Stifel Nicolaus americanbankingnews.com - April 20 at 10:46 AM
	Jazz Pharmaceuticals (NASDAQ:JAZZ) PT Raised to $202.00 at Stifel Nicolaus americanbankingnews.com - April 20 at 10:08 AM
	Stifel Nicolaus Raises Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target to $202.00 americanbankingnews.com - April 20 at 10:08 AM
	BRIEF-Jazz Pharmaceuticals Presents Phase 3 Study Results Of Xywav Oral Solution In Adults With Idiopathic Hypersomnia At 2021 American Academy Of Neurology Annual Meeting msn.com - April 20 at 9:18 AM
	Jazz Pharmaceuticals Presents Phase 3 Study Results of Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution in Adult Patients with Idiopathic Hypersomnia at 2021 American Academy of Neurology Annual Meeting finance.yahoo.com - April 20 at 9:18 AM
	Jazz Pharmaceuticals Announces Proposed Private Offering of Senior Secured Notes finance.yahoo.com - April 20 at 9:18 AM
	Jazz Pharmaceuticals to Report 2021 First Quarter Financial Results on May 4, 2021 finance.yahoo.com - April 19 at 5:27 PM
	Jazz Pharmaceuticals (NASDAQ:JAZZ) Has A Rock Solid Balance Sheet ca.finance.yahoo.com - April 17 at 1:11 AM
	Stifel Nicolaus Stick to Their Buy Rating for Jazz Pharmaceuticals investing.com - April 15 at 6:08 PM
	Stifel Nicolaus Increases Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target to $202.00 americanbankingnews.com - April 14 at 8:54 AM
	US FDA accepts and grants priority review status to Jazz’s sNDA for Xywav to treat idiopathic hypersomnia pharmabiz.com - April 14 at 5:17 AM
	Jazz Pharmaceuticals Announces FDA Acceptance and… pharmiweb.com - April 13 at 8:36 AM
	Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental New Drug Application for Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution in Idiopathic Hypersomnia finance.yahoo.com - April 12 at 9:11 AM
	Fitch Assigns First-Time Rating of 'BB-' to Jazz Pharmaceuticals plc fitchratings.com - April 9 at 10:13 PM
	Jazz Pharmaceuticals plc (NASDAQ:JAZZ) CEO Sells $247,440.00 in Stock americanbankingnews.com - April 6 at 7:36 PM
	Jazz Pharmaceuticals (NASDAQ:JAZZ) versus OptiNose (NASDAQ:OPTN) Head to Head Contrast americanbankingnews.com - April 6 at 10:22 AM
	Oyster Point Pharma Announces New Appointment to Board of Directors finance.yahoo.com - April 5 at 6:22 AM
	Zacks: Brokerages Anticipate Jazz Pharmaceuticals plc (NASDAQ:JAZZ) to Announce $3.69 Earnings Per Share americanbankingnews.com - April 4 at 10:16 PM
	US FDA approves revised label for Jazz Pharma’s Vyxeos to include new indication to treat secondary acute myeloid leukemia in pediatric patients pharmabiz.com - April 1 at 9:51 AM
	Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target Raised to $176.00 marketbeat.com - April 1 at 8:51 AM
	Jazz Pharmaceuticals (NASDAQ:JAZZ) PT Raised to $176.00 americanbankingnews.com - April 1 at 8:16 AM

Date	Company	Brokerage	Action
4/20/2021	Zai Lab	SVB Leerink	Boost Price Target
4/13/2021	Zai Lab	The Goldman Sachs Group	Boost Price Target
4/13/2021	Zai Lab	Guggenheim	Boost Price Target
2/8/2021	Zai Lab	Jefferies Financial Group	Boost Price Target
11/16/2020	Zai Lab	JPMorgan Chase & Co.	Boost Price Target
12/30/2019	Zai Lab	Citigroup	Boost Price Target
9/4/2019	Zai Lab	China Renaissance Securities	Initiated Coverage
7/12/2019	Zai Lab	Bank of America	Initiated Coverage
7/5/2019	Zai Lab	Macquarie	Initiated Coverage
1/29/2019	Zai Lab	Credit Suisse Group	Initiated Coverage
3/30/2021	Ascendis Pharma A/S	Oppenheimer	Downgrade
3/18/2021	Ascendis Pharma A/S	Canaccord Genuity	Boost Price Target
3/11/2021	Ascendis Pharma A/S	Stifel Nicolaus	Initiated Coverage
12/17/2020	Ascendis Pharma A/S	Berenberg Bank	Initiated Coverage
11/13/2020	Ascendis Pharma A/S	Morgan Stanley	Boost Price Target
11/12/2020	Ascendis Pharma A/S	Wells Fargo & Company	Boost Price Target
9/30/2020	Ascendis Pharma A/S	Wedbush	Boost Price Target
5/20/2020	Ascendis Pharma A/S	CSFB	Boost Price Target
2/8/2021	Arrowhead Pharmaceuticals	B. Riley	Boost Price Target
2/5/2021	Arrowhead Pharmaceuticals	Piper Sandler	Boost Price Target
2/5/2021	Arrowhead Pharmaceuticals	Chardan Capital	Boost Price Target
2/5/2021	Arrowhead Pharmaceuticals	HC Wainwright	Boost Price Target
12/21/2020	Arrowhead Pharmaceuticals	Robert W. Baird	Downgrade
12/15/2020	Arrowhead Pharmaceuticals	UBS Group	Initiated Coverage
11/24/2020	Arrowhead Pharmaceuticals	Royal Bank of Canada	Boost Price Target
11/24/2020	Arrowhead Pharmaceuticals	Cantor Fitzgerald	Boost Price Target
11/19/2020	Arrowhead Pharmaceuticals	Smith Barney Citigroup	Initiated Coverage
11/19/2020	Arrowhead Pharmaceuticals	Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell	Initiated Coverage
4/13/2021	ACADIA Pharmaceuticals	Mizuho	Reiterated Rating
4/5/2021	ACADIA Pharmaceuticals	Raymond James	Downgrade
4/5/2021	ACADIA Pharmaceuticals	Needham & Company LLC	Lower Price Target
2/24/2021	Jazz Pharmaceuticals	Cowen	Boost Price Target
11/3/2020	Jazz Pharmaceuticals	Barclays	Boost Price Target
10/20/2020	Jazz Pharmaceuticals	Truist	Boost Price Target

(Data available from 4/23/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources